RBC Capital analyst Gregory Renza raised the firm’s price target on Viridian Therapeutics (VRDN) to $47 from $44 and keeps an Outperform rating on the shares. The company’s positive THRIVE-2 topline for veligrotug – Veli – in chronic TED comes as a second big win for the program and could be the game changer on differentiation that Viridian bulls have been waiting for, the analyst tells investors in a research note. Importantly, Veli’s 56% diplopia response and complete resolution in 32% of patients marks the first pivotal to demonstrate statistically significant diplopia improvement and serves as a key differentiator to Amgen’s (AMGN) Tepezza, the firm added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz
- Morning Movers: Viridian and Edgewise jump following successful trials
- Viridian Therapeutics Achieves Milestone in Phase 3 Trial
- Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
- Viridian Therapeutics initiated with a Buy at TD Cowen